95 related articles for article (PubMed ID: 16194893)
1. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
4. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
5. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
[TBL] [Abstract][Full Text] [Related]
7. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
Benboubker L; Valat C; Linassier C; Cartron G; Delain M; Bout M; Fetissof F; Lefranq T; Lamagnere JP; Colombat P
Ann Oncol; 2000 Nov; 11(11):1485-91. PubMed ID: 11142490
[TBL] [Abstract][Full Text] [Related]
8. An improved prognostic parameter for non-Hodgkin's lymphoma based on the combination of three serum tumor markers.
Gui W; Wang T; Wang J; Wang L; He J; Yang B; Zhao Z; Zhang H; Zhang Q
Int J Biol Markers; 2008; 23(4):207-13. PubMed ID: 19199267
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
[TBL] [Abstract][Full Text] [Related]
10. Serum CA 125 levels in children with non-Hodgkin's lymphoma.
Kutluk T; Varan A; Erbaş B; Büyükpamukçu M
Pediatr Hematol Oncol; 1999; 16(4):311-9. PubMed ID: 10407867
[TBL] [Abstract][Full Text] [Related]
11. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
12. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
Dilek I; Ayakta H; Demir C; Meral C; Ozturk M
Clin Lab Haematol; 2005 Feb; 27(1):51-5. PubMed ID: 15686508
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
14. [Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma].
Chen W; Luo RC; Fan WW; Ma SD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):227-8, 230. PubMed ID: 16503538
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
16. CA 125 elevations in patients with malignant lymphomas.
Fehm T; Beck E; Valerius T; Gramatzki M; Jäger W
Tumour Biol; 1998; 19(4):283-9. PubMed ID: 9679739
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic analysis of 125 cases of non-Hodgkin's lymphoma.
Liu L; Zhang M; Zou P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):547-50. PubMed ID: 18549626
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
20. CA-125: a tumor marker in non-Hodgkin's lymphomas?
Pabst T; Ludwig C
J Clin Oncol; 1995 Jul; 13(7):1827-8. PubMed ID: 7602374
[No Abstract] [Full Text] [Related]
[Next] [New Search]
